Literature DB >> 35990786

Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH).

Giada Sebastiani1, Keyur Patel2, Vlad Ratziu3, Jordan J Feld2, Brent A Neuschwander-Tetri4, Massimo Pinzani5, Salvatore Petta6, Annalisa Berzigotti7, Peter Metrakos8, Naglaa Shoukry9, Elizabeth M Brunt10, An Tang11, Jeremy F Cobbold12, Jean-Marie Ekoe13, Karen Seto14, Peter Ghali15, Stéphanie Chevalier16, Quentin M Anstee17, Heather Watson18, Harpreet Bajaj19, James Stone20, Mark G Swain21, Alnoor Ramji22.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) affects approximately 8 million Canadians. NAFLD refers to a disease spectrum ranging from bland steatosis to non-alcoholic steatohepatitis (NASH). Nearly 25% of patients with NAFLD develop NASH, which can progress to liver cirrhosis and related end-stage complications. Type 2 diabetes and obesity represent the main risk factors for the disease. The Canadian NASH Network is a national collaborative organization of health care professionals and researchers with a primary interest in enhancing understanding, care, education, and research around NAFLD, with a vision of best practices for this disease state. At the 1st International Workshop of the CanNASH network in April 2021, a joint event with the single topic conference of the Canadian Association for the Study of the Liver (CASL), clinicians, epidemiologists, basic scientists, and community members came together to share their work under the theme of NASH. This symposium also marked the initiation of collaborations between Canadian and other key opinion leaders in the field representative of international liver associations. The main objective is to develop a policy framework that outlines specific targets, suggested activities, and evidence-based best practices to guide provincial, territorial, and federal organizations in developing multidisciplinary models of care and strategies to address this epidemic.
Copyright © 2022 Canadian Association for the Study of the Liver.

Entities:  

Keywords:  Canadian NASH Network; biomedical; clinical; diabetes; epidemiological; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; public health

Year:  2022        PMID: 35990786      PMCID: PMC9231423          DOI: 10.3138/canlivj-2021-0030

Source DB:  PubMed          Journal:  Can Liver J        ISSN: 2561-4444


  144 in total

Review 1.  Update on the pathophysiology of liver fibrosis.

Authors:  Massimo Pinzani; Jose Macias-Barragan
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-08       Impact factor: 3.869

Review 2.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

3.  Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis.

Authors:  Jonathan G Stine; Neeral L Shah; Curtis K Argo; Shawn J Pelletier; Stephen H Caldwell; Patrick G Northup
Journal:  Liver Transpl       Date:  2015-07-01       Impact factor: 5.799

4.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

Authors:  Hannes Hagström; Patrik Nasr; Mattias Ekstedt; Ulf Hammar; Per Stål; Rolf Hultcrantz; Stergios Kechagias
Journal:  J Hepatol       Date:  2017-08-10       Impact factor: 25.083

5.  Obesity in adults: a clinical practice guideline.

Authors:  Sean Wharton; David C W Lau; Michael Vallis; Arya M Sharma; Laurent Biertho; Denise Campbell-Scherer; Kristi Adamo; Angela Alberga; Rhonda Bell; Normand Boulé; Elaine Boyling; Jennifer Brown; Betty Calam; Carol Clarke; Lindsay Crowshoe; Dennis Divalentino; Mary Forhan; Yoni Freedhoff; Michel Gagner; Stephen Glazer; Cindy Grand; Michael Green; Margaret Hahn; Raed Hawa; Rita Henderson; Dennis Hong; Pam Hung; Ian Janssen; Kristen Jacklin; Carlene Johnson-Stoklossa; Amy Kemp; Sara Kirk; Jennifer Kuk; Marie-France Langlois; Scott Lear; Ashley McInnes; David Macklin; Leen Naji; Priya Manjoo; Marie-Philippe Morin; Kara Nerenberg; Ian Patton; Sue Pedersen; Leticia Pereira; Helena Piccinini-Vallis; Megha Poddar; Paul Poirier; Denis Prud'homme; Ximena Ramos Salas; Christian Rueda-Clausen; Shelly Russell-Mayhew; Judy Shiau; Diana Sherifali; John Sievenpiper; Sanjeev Sockalingam; Valerie Taylor; Ellen Toth; Laurie Twells; Richard Tytus; Shahebina Walji; Leah Walker; Sonja Wicklum
Journal:  CMAJ       Date:  2020-08-04       Impact factor: 8.262

6.  The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content.

Authors:  Yftach Gepner; Ilan Shelef; Oded Komy; Noa Cohen; Dan Schwarzfuchs; Nitzan Bril; Michal Rein; Dana Serfaty; Shira Kenigsbuch; Hila Zelicha; Anat Yaskolka Meir; Lilac Tene; Avital Bilitzky; Gal Tsaban; Yoash Chassidim; Benjamin Sarusy; Uta Ceglarek; Joachim Thiery; Michael Stumvoll; Matthias Blüher; Meir J Stampfer; Assaf Rudich; Iris Shai
Journal:  J Hepatol       Date:  2019-05-08       Impact factor: 25.083

Review 7.  Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.

Authors:  Fernando Bril; Kenneth Cusi
Journal:  Diabetes Care       Date:  2017-03       Impact factor: 19.112

8.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Authors:  Zobair Younossi; Maria Stepanova; Janus P Ong; Ira M Jacobson; Elisabetta Bugianesi; Ajay Duseja; Yuichiro Eguchi; Vincent W Wong; Francesco Negro; Yusuf Yilmaz; Manuel Romero-Gomez; Jacob George; Aijaz Ahmed; Robert Wong; Issah Younossi; Mariam Ziayee; Arian Afendy
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-14       Impact factor: 11.382

9.  Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes.

Authors:  Stefano Bonapace; Gianluca Perseghin; Giulio Molon; Guido Canali; Lorenzo Bertolini; Giacomo Zoppini; Enrico Barbieri; Giovanni Targher
Journal:  Diabetes Care       Date:  2011-12-30       Impact factor: 19.112

10.  Association between non-alcoholic fatty liver disease and cancer incidence rate.

Authors:  Gi-Ae Kim; Han Chu Lee; Jaewon Choe; Min-Ju Kim; Min Jung Lee; Hye-Sook Chang; In Young Bae; Hong-Kyu Kim; Jihyun An; Ju Hyun Shim; Kang Mo Kim; Young-Suk Lim
Journal:  J Hepatol       Date:  2017-11-02       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.